LPCN
Lipocine Inc.
Price Chart
Latest Quote
$2.47
-0.06 (-2.37%)
Current Price
| Previous Close | $2.53 |
| Open | $2.53 |
| Day High | $2.59 |
| Day Low | $2.43 |
| Volume | 63,041 |
Stock Information
| Shares Outstanding | 8.24M |
| Cash Equivalents | $24.73M |
| Revenue | $2.00M |
| Net Income | $-11.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $20.36M |
| EPS (TTM) | $-1.96 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.37M |
| Sales | $2.00M |
| Income | $-11.43M |
| Book/sh | $3.05 |
| Cash/sh | $3.00 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 9.87 |
| Current Ratio | 9.99 |
Returns & Margins
| ROA | -33.07% |
| ROE | -54.41% |
| Gross Margin | 100.00% |
| Operating Margin | -3224.09% |
Ownership
| Insider Ownership | 4.51% |
| Institutional Ownership | 44.29% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.99 |
| P/S | 10.17 |
| P/B | 0.81 |
Analyst Data
| Recommendation | none |
| Target Price | $6.00 |
Technical Indicators
| SMA20 | $2.24 |
| SMA50 | $2.30 |
| SMA200 | $4.67 |
| RSI | 64.29 |
| ATR | 0.1842 |
| Shares Float | 6.91M |
| Short Float | 1.12% |
| Short Ratio | 0.89 |
| Volatility | 0.46 |
| Rel Volume | 0.53 |
Performance History
| Week | +7.39% |
| Month | +9.29% |
| Quarter | -66.44% |
| 6 Months | -41.88% |
| YTD | -69.12% |
| Year | -21.34% |
| 3 Years | -49.07% |
| 5 Years | -89.16% |
| 10 Years | -97.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $2.47 | 63,200 |
| 2026-06-23 | $2.53 | 207,800 |
| 2026-06-22 | $2.29 | 93,900 |
| 2026-06-18 | $2.33 | 122,400 |
| 2026-06-17 | $2.34 | 159,300 |
| 2026-06-16 | $2.30 | 87,900 |
| 2026-06-15 | $2.29 | 71,200 |
| 2026-06-12 | $2.26 | 202,700 |
| 2026-06-11 | $2.20 | 310,400 |
| 2026-06-10 | $1.98 | 110,600 |
| 2026-06-09 | $2.05 | 95,900 |
| 2026-06-08 | $2.04 | 95,800 |
| 2026-06-05 | $2.05 | 87,600 |
| 2026-06-04 | $2.21 | 75,700 |
| 2026-06-03 | $2.19 | 59,900 |
| 2026-06-02 | $2.25 | 140,400 |
| 2026-06-01 | $2.28 | 148,900 |
| 2026-05-29 | $2.25 | 81,700 |
| 2026-05-28 | $2.26 | 74,000 |
| 2026-05-27 | $2.28 | 85,200 |
| 2026-05-26 | $2.26 | 152,300 |
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
đ° Latest News
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T19:15:01Z
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T13:30:02Z
Lipocine: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-10T10:25:22ZLipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-02-27T12:44:00Z
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-02-26T23:00:07Z
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15
Insider Monkey âĸ 2026-02-11T20:16:17Z
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2025-11-06T14:10:02Z
Lipocine: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-06T13:12:45ZLipocine: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-05T10:21:42ZLipocine begins dosing in Phase III postpartum depression trial of LPCN 1154
Clinical Trials Arena âĸ 2025-06-27T11:28:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $8,583,919 | $7,351,753 | $10,175,251 | $8,556,888 |
| Cost Of Revenue | $8,583,919 | $7,351,753 | $10,175,251 | $8,556,888 |
| Total Revenue | $1,976,677 | $11,198,144 | $-2,850,818 | $500,000 |
| Operating Revenue | $1,976,677 | $11,198,144 | $-2,850,818 | $500,000 |
| Expenses | ||||
| Total Expenses | $12,348,056 | $12,353,179 | $15,080,139 | $12,619,375 |
| Net Non Operating Interest Income Expense | $744,074 | $1,146,902 | $1,366,940 | $545,480 |
| Operating Expense | $3,764,137 | $5,001,426 | $4,904,888 | $4,062,487 |
| General And Administrative Expense | $3,764,137 | $5,001,426 | $4,904,888 | $4,062,487 |
| Other Income Expense | - | $17,166 | $212,690 | $815,940 |
| Interest Expense | - | - | $0 | $27,098 |
| Interest Expense Non Operating | - | - | $0 | $27,098 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,627,505 | $8,352 | $-16,352,082 | $-10,758,636 |
| Net Interest Income | $744,074 | $1,146,902 | $1,366,940 | $545,480 |
| Interest Income | $744,074 | $1,146,902 | $1,366,940 | $572,578 |
| Normalized Income | $-9,627,505 | $-7,520 | $-16,520,107 | $-11,403,229 |
| Net Income From Continuing And Discontinued Operation | $-9,627,505 | $8,352 | $-16,352,082 | $-10,758,636 |
| Total Operating Income As Reported | $-10,371,379 | $-1,155,035 | $-17,930,957 | $-12,119,375 |
| Average Dilution Earnings | $0 | $-17,166 | $-212,690 | $-565,940 |
| Net Income Common Stockholders | $-9,627,505 | $8,352 | $-16,352,171 | $-10,758,636 |
| Net Income | $-9,627,505 | $8,352 | $-16,352,082 | $-10,758,636 |
| Net Income Including Noncontrolling Interests | $-9,627,505 | $8,352 | $-16,352,082 | $-10,758,636 |
| Net Income Continuous Operations | $-9,627,505 | $8,352 | $-16,352,082 | $-10,758,636 |
| Pretax Income | $-9,627,305 | $9,033 | $-16,351,327 | $-10,757,955 |
| Interest Income Non Operating | $744,074 | $1,146,902 | $1,366,940 | $572,578 |
| Operating Income | $-10,371,379 | $-1,155,035 | $-17,930,957 | $-12,119,375 |
| Gross Profit | $-6,607,242 | $3,846,391 | $-13,026,069 | $-8,056,888 |
| Special Income Charges | - | - | $0 | $250,000 |
| Per Share | ||||
| Diluted EPS | $-1.77 | $0.00 | $-3.14 | $-2.21 |
| Basic EPS | $-1.77 | $0.00 | $-3.10 | $-2.04 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $1,294 | $44,665 | $171,347 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,310,597 | $-1,131,095 | $-18,114,986 | $-11,537,344 |
| Reconciled Depreciation | $60,782 | $41,106 | $28,661 | $9,453 |
| EBITDA (Bullshit earnings) | $-10,310,597 | $-1,113,929 | $-17,902,296 | $-10,721,404 |
| EBIT | $-10,371,379 | $-1,155,035 | $-17,930,957 | $-10,730,857 |
| Diluted Average Shares | $5,708,238 | $5,422,604 | $5,269,671 | $5,227,996 |
| Basic Average Shares | $5,448,871 | $5,338,957 | $5,269,671 | $5,203,367 |
| Diluted NI Availto Com Stockholders | $-9,627,505 | $-8,814 | $-16,564,861 | $-11,324,576 |
| Tax Provision | $200 | $681 | $755 | $681 |
| Selling General And Administration | $3,764,137 | $5,001,426 | $4,904,888 | $4,062,487 |
| Other Gand A | $3,764,137 | $5,001,426 | $4,904,888 | $4,062,487 |
| Total Unusual Items | - | $17,166 | $212,690 | $815,940 |
| Total Unusual Items Excluding Goodwill | - | $17,166 | $212,690 | $815,940 |
| Gain On Sale Of Security | - | $17,166 | $212,690 | $565,940 |
| Preferred Stock Dividends | - | - | $89 | - |
| Other Special Charges | - | - | - | $-250,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Total Assets | $17,005,612 | $22,510,501 | $23,001,072 | $37,542,922 |
| Total Non Current Assets | $128,046 | $188,828 | $139,848 | $3,407,842 |
| Other Non Current Assets | $23,753 | $23,753 | $23,753 | $23,753 |
| Current Assets | $16,877,566 | $22,321,673 | $22,861,224 | $34,135,080 |
| Other Current Assets | $787,600 | $476,510 | $773,424 | $945,319 |
| Receivables | $1,159,579 | $211,852 | $52,254 | $659,855 |
| Other Receivables | $1,145,390 | $91,405 | - | $579,428 |
| Accrued Interest Receivable | $14,189 | $120,447 | $52,254 | $80,427 |
| Cash Cash Equivalents And Short Term Investments | $14,930,387 | $21,633,311 | $22,035,546 | $32,529,906 |
| Cash And Cash Equivalents | $5,205,842 | $6,205,926 | $4,771,758 | $3,148,496 |
| Non Current Accounts Receivable | - | - | - | $3,252,500 |
| Investmentin Financial Assets | - | - | - | $0 |
| Non Current Deferred Assets | - | - | - | - |
| Restricted Cash | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | - |
| Current Debt And Capital Lease Obligation | - | - | - | - |
| Current Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,528,196 | $1,512,936 | $2,631,629 | $1,907,982 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $229,856 |
| Current Liabilities | $2,528,196 | $1,512,936 | $2,631,629 | $1,678,126 |
| Current Deferred Liabilities | $320,000 | $320,000 | $0 | - |
| Payables And Accrued Expenses | $2,208,196 | $1,192,936 | $2,614,463 | $1,678,126 |
| Payables | $971,822 | $271,696 | $1,395,977 | $600,388 |
| Accounts Payable | $971,822 | $271,696 | $1,395,977 | $600,388 |
| Derivative Product Liabilities | - | - | $0 | $229,856 |
| Other Current Liabilities | - | - | $17,166 | - |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Total Equity Gross Minority Interest | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Stockholders Equity | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Gains Losses Not Affecting Retained Earnings | $4,445 | $9,138 | $7,259 | $-20,321 |
| Other Equity Adjustments | $4,445 | $9,138 | $7,259 | $-20,321 |
| Retained Earnings | $-209,396,367 | $-199,768,862 | $-199,777,214 | $-183,425,043 |
| Other | ||||
| Treasury Shares Number | $336 | $336 | $336 | $335 |
| Ordinary Shares Number | $6,158,443 | $5,347,940 | $5,315,830 | $5,206,517 |
| Share Issued | $6,158,779 | $5,348,276 | $5,316,166 | $5,206,852 |
| Tangible Book Value | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Invested Capital | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Working Capital | $14,349,370 | $20,808,737 | $20,229,595 | $32,456,954 |
| Total Capitalization | $14,477,416 | $20,997,565 | $20,369,443 | $35,634,940 |
| Treasury Stock | $40,712 | $40,712 | $40,712 | $40,712 |
| Additional Paid In Capital | $223,901,106 | $220,789,138 | $220,171,250 | $219,112,164 |
| Capital Stock | $8,944 | $8,863 | $8,860 | $8,852 |
| Common Stock | $8,944 | $8,863 | $8,860 | $8,852 |
| Current Deferred Revenue | $320,000 | $320,000 | $0 | - |
| Current Accrued Expenses | $1,236,374 | $921,240 | $1,218,486 | $1,077,738 |
| Net PPE | $104,293 | $165,075 | $116,095 | $131,589 |
| Accumulated Depreciation | $-1,284,079 | $-1,223,297 | $-1,182,191 | $-1,153,530 |
| Gross PPE | $1,388,372 | $1,388,372 | $1,298,286 | $1,285,119 |
| Machinery Furniture Equipment | $1,388,372 | $1,388,372 | $1,298,286 | $1,285,119 |
| Other Short Term Investments | $9,724,545 | $15,427,385 | $17,263,788 | $29,381,410 |
| Preferred Stock | - | - | - | $0 |
| Investments And Advances | - | - | - | $0 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,760,721 | $-1,311,319 | $-11,879,158 | $-12,102,650 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,760,721 | $-1,221,233 | $-11,865,991 | $-11,968,819 |
| Cash Flow From Continuing Operating Activities | $-9,760,721 | $-1,221,233 | $-11,865,991 | $-11,968,819 |
| Operating Gains Losses | - | $-17,166 | $-212,690 | $-565,940 |
| Investing Activities | ||||
| Investing Cash Flow | $5,891,085 | $2,446,061 | $13,084,686 | $14,293,707 |
| Cash Flow From Continuing Investing Activities | $5,891,085 | $2,446,061 | $13,084,686 | $14,293,707 |
| Capital Expenditure | - | $-90,086 | $-13,167 | $-133,831 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,869,552 | $209,340 | $404,567 | $0 |
| Financing Cash Flow | $2,869,552 | $209,340 | $404,567 | $-2,126,944 |
| Cash Flow From Continuing Financing Activities | $2,869,552 | $209,340 | $404,567 | $-2,126,944 |
| Net Common Stock Issuance | $2,869,552 | $209,340 | $404,567 | $-21,700 |
| Common Stock Issuance | $2,869,552 | $209,340 | $404,567 | $0 |
| Repurchase Of Capital Stock | - | - | - | $-21,700 |
| Other | ||||
| Income Tax Paid Supplemental Data | $200 | $681 | $225 | $200 |
| End Cash Position | $5,205,842 | $6,205,926 | $4,771,758 | $3,148,496 |
| Beginning Cash Position | $6,205,926 | $4,771,758 | $3,148,496 | $2,950,552 |
| Changes In Cash | $-1,000,084 | $1,434,168 | $1,623,262 | $197,944 |
| Net Investment Purchase And Sale | $5,891,085 | $2,536,147 | $13,097,853 | $14,427,538 |
| Sale Of Investment | $20,600,000 | $35,400,000 | $36,000,000 | $59,502,000 |
| Purchase Of Investment | $-14,708,915 | $-32,863,853 | $-22,902,147 | $-45,074,462 |
| Net PPE Purchase And Sale | $0 | $-90,086 | $-13,167 | $-133,831 |
| Purchase Of PPE | $0 | $-90,086 | $-13,167 | $-133,831 |
| Change In Working Capital | $-243,557 | $-964,211 | $2,007,528 | $-923,630 |
| Change In Payables And Accrued Expense | $1,015,260 | $-1,421,527 | $936,337 | $-627,674 |
| Change In Accrued Expense | $315,134 | $-297,246 | $140,748 | $61,280 |
| Change In Payable | $700,126 | $-1,124,281 | $795,589 | $-688,954 |
| Change In Account Payable | $700,126 | $-1,124,281 | $795,589 | $-688,954 |
| Change In Prepaid Assets | $-311,090 | $114,104 | $333,085 | $569,146 |
| Change In Receivables | $-947,727 | $23,212 | $738,106 | $384,898 |
| Stock Based Compensation | $242,497 | $408,551 | $654,438 | $636,140 |
| Amortization Of Securities | $-192,938 | $-697,865 | $-952,651 | $-122,048 |
| Depreciation Amortization Depletion | $60,782 | $41,106 | $28,661 | $9,453 |
| Depreciation And Amortization | $60,782 | $41,106 | $28,661 | $9,453 |
| Depreciation | $60,782 | $41,106 | $28,661 | $9,453 |
| Net Income From Continuing Operations | $-9,627,505 | $8,352 | $-16,352,082 | $-10,758,636 |
| Change In Other Working Capital | - | $320,000 | - | - |
| Asset Impairment Charge | - | $0 | $2,960,805 | $0 |
| Gain Loss On Investment Securities | - | $-17,166 | $-212,690 | $-565,940 |
| Repayment Of Debt | - | - | $0 | $-2,316,667 |
| Interest Paid Supplemental Data | - | - | $0 | $21,256 |
| Proceeds From Stock Option Exercised | - | - | $0 | $211,423 |
| Net Issuance Payments Of Debt | - | - | $0 | $-2,316,667 |
| Net Long Term Debt Issuance | - | - | $0 | $-2,316,667 |
| Long Term Debt Payments | - | - | $0 | $-2,316,667 |
| Change In Other Current Liabilities | - | - | $0 | $-1,250,000 |
| Common Stock Payments | - | - | - | $-21,700 |
| Other Non Cash Items | - | - | - | $-244,158 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-24